Showing 3,041 - 3,060 results of 3,149 for search '"breast"', query time: 0.08s Refine Results
  1. 3041
  2. 3042

    Exploring the metabolic dynamics, storage stability, and functional potential of Lacticaseibacillus rhamnosus Probio-M9-fermented milk by Xiaoye Liu, Kaiyang Liu, Jie Yang, Hui Qiao, Lai-Yu Kwok, Wenyi Zhang

    Published 2025-02-01
    “…ABSTRACT: Lacticaseibacillus rhamnosus Probio-M9 (Probio-M9), a probiotic strain sourced from healthy breast milk, is recognized for its resilience to gastric and bile acids, along with its potential health benefits for infants. …”
    Get full text
    Article
  3. 3043
  4. 3044
  5. 3045

    Rhoifolin Suppresses Cell Proliferation and Induces Apoptosis in Hepatocellular Carcinoma Cells In Vitro and In Vivo by Ruolan Chen, Zufa Sabeel, Lu Ying, Youfeng Liang, Rui Guo, Mingxuan Hao, Xiaoyang Chen, Wenjing Zhang, Jian Dong, Yan Liu, Changyuan Yu, Zhao Yang

    Published 2025-01-01
    “…Rhoifolin (ROF), a flavonoid constituent, has previously been shown to suppress the proliferation of breast and pancreatic cancer cells. However, its inhibitory effect on HCC has remained unexplored. …”
    Get full text
    Article
  6. 3046
  7. 3047
  8. 3048

    Integrative analysis of miRNA expression data reveals a minimal signature for tumour cells classification by Sabrina Napoletano, David Dannhauser, Paolo Antonio Netti, Filippo Causa

    Published 2025-01-01
    “…In this study, we present a comprehensive integrative approach that utilizes transcriptomic data from lung, breast, and melanoma cancer cell lines to identify specific expression patterns. …”
    Get full text
    Article
  9. 3049
  10. 3050

    Modelling the potential clinical and economic impact of universal antenatal hepatitis C (HCV) screening and providing treatment for pregnant women with HCV and their infants in Egy... by Giuseppe Indolfi, Diana M Gibb, Aya Mostafa, Sarah Pett, Yazdan Yazdanpanah, Sylvie Deuffic-Burban, Anthony E Ades, Karen Scott, Ali Judd, Nadia Hachicha-Maalej, Clotilde Lepers, Intira Jeannie Collins, Manal H El Sayed

    Published 2024-04-01
    “…This study assesses the cost-effectiveness of several screening and treatment strategies for pregnant women and infants in Egypt.Design A Markov model was developed to simulate the cascade of care and HCV disease progression among pregnant women and their infants according to different screening and treatment strategies, which included: targeted versus universal antenatal screening; treatment of women in pregnancy or deferred till after breast feeding; treatment of infected children at 3 years vs 12 years. …”
    Get full text
    Article
  11. 3051
  12. 3052

    Mycochemistry, antioxidant, anticancer activity, and molecular docking of compounds of F12 of ethyl acetate extract of Astraeus asiaticus with BcL2 and Caspase 3 by Swapan Kumar Ghosh, Koushik Pandey, Madhuparna Ghosh, Pradip Kumar Sur

    Published 2025-02-01
    “…We have tried to focus on anticancer compounds derived from the partial purification (F12) of mushroom extract (AAEA) from this edible mushroom against cancer (cervical, lung, and breast) cell lines. After 24 h of treatment, the percentages of cell growth inhibition of HeLa, MCF-7, and A549 cell lines by highest concentration (1500 µg. mL− 1) of F12 were 92.03 ± 6.21 a, 90.38 ± 4.53a, and 87.51 ± 5.36a % respectively and the IC50 values were 701 ± 11.54, 728.71 ± 10.53, and 806.88 ± 11.52 µg. mL− 1 respectively but the growth of normal cell HEK 293T was inhibited slightly (3.0%). …”
    Get full text
    Article
  13. 3053

    RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia by Tim Kong, Angelo B. A. Laranjeira, Christopher T. Letson, LaYow Yu, Shuyang Lin, Jared S. Fowles, Daniel A. C. Fisher, Sherwin Ng, Wei Yang, Fan He, Minyoung Youn, Kailen Mark, Ana San Jose, Jingxian Liu, Alexander B. Kim, Maggie J. Cox, Mary C. Fulbright, Aarthi Jayanthan, Gerrit Los, Stacey L. Rentschler, Li Ding, Kathleen M. Sakamoto, Sandra E. Dunn, Grant A. Challen, Stephen T. Oh

    Published 2025-01-01
    “…We further evaluate a therapeutic approach utilizing a first-in-class RSK inhibitor, PMD-026, currently in Phase 2 development for breast cancer, for use in myeloid malignancies. Treatment with PMD-026 suppressed disease burden across seven syngeneic and patient-derived xenograft leukemia mouse models spanning the spectrum of driver and disease-modifying mutations. …”
    Get full text
    Article
  14. 3054

    Clinical and biochemical characteristics of patients with acromegaly and normal or increased prolactin levels by Yuliya A. Kukushkina, Irena A. Ilovayskaya

    Published 2024-12-01
    “…Results: Hyperprolactinemia was significantly less common, than acromegaly without hyperprolactinemia, associated with acromegalic enlargement of the face (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.19–0.62, р 0.001), hands and feet enlargement (OR 0.06, 95% CI 0.03–0.12, р 0.001), but more common with visual field derangement (OR 2.8, 95% CI 1.06–7.39, р = 0.043), menstrual cycle abnormalities in women (OR 4.11, 95% CI 2.14–7.88, р 0.001) and breast discharge (OR 18.71, 95% CI 4–87.61, р 0.001). …”
    Get full text
    Article
  15. 3055

    First Clinical Experience of <sup>68</sup>Ga-FAPI PET/CT in Tertiary Cancer Center: Identifying Pearls and Pitfalls by Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Ula Al-Rasheed, Dhuha Al-Adhami, Feras Istatieh, Farah Anwar, Marwah Abdulrahman, Rula Amarin, Issa Mohamad, Asem Mansour

    Published 2025-01-01
    “…<b>Methods:</b> A total of 48 patients with biopsy-confirmed solid tumors underwent 77 <sup>68</sup>Ga-FAPI PET/CT examinations for molecular imaging assessment, encompassing neoplasms originating from the gastrointestinal tract, head and neck, hepatobiliary system, pancreas, breast, and lung. <b>Results:</b> Notably, pancreaticobiliary tumors exhibited the highest tracer uptake, with mean maximum standardized uptake values (SUVmax) and tumor-to-background ratios (TBR) surpassing 10. …”
    Get full text
    Article
  16. 3056
  17. 3057

    Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles. by Adriane Fugh-Berman, Christina Pike McDonald, Alicia M Bell, Emily Catherine Bethards, Anthony R Scialli

    Published 2011-03-01
    “…Scientific accuracy was assessed based on whether or not the findings of the WHI were accurately reported using two criteria: (1) Acknowledgment or lack of denial of the risk of breast cancer diagnosis associated with hormone therapy, and (2) acknowledgment that hormone therapy did not benefit cardiovascular disease endpoints. …”
    Get full text
    Article
  18. 3058

    Exploring the role of splicing in TP53 variant pathogenicity through predictions and minigene assays by Cristina Fortuno, Inés Llinares-Burguet, Daffodil M. Canson, Miguel de la Hoya, Elena Bueno-Martínez, Lara Sanoguera-Miralles, Sonsoles Caldes, Paul A. James, Eladio A. Velasco-Sampedro, Amanda B. Spurdle

    Published 2025-01-01
    “…Methods We conducted splicing analyses using a minigene construct containing TP53 exons 2 to 9 transfected into human breast cancer SKBR3 cells, and compared results against different splice prediction methods, including correlation with the SpliceAI-10k calculator. …”
    Get full text
    Article
  19. 3059

    T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint pr... by Stephanie Schlichtner, Inna M Yasinska, Gurprit S Lall, Steffen M Berger, Sabrina Ruggiero, Dietmar Cholewa, Nijas Aliu, Bernhard F Gibbs, Elizaveta Fasler-Kan, Vadim V Sumbayev

    Published 2023-01-01
    “…Recent evidence demonstrated that galectin-9 is highly expressed in a wide range of human malignancies including the most aggressive tumors, such as high-grade glioblastomas and pancreatic ductal adenocarcinomas, as well as common malignancies such as breast, lung and colorectal cancers. However, solid tumor cells at rest are known to secrete either very low amounts of galectin-9 or, in most of the cases, do not secrete it at all. …”
    Get full text
    Article
  20. 3060

    CHAT-S study protocol: A randomized controlled trial of a health insurance literacy education program for young adult cancer survivors by Mary Killela, Cindy A. Turner, Amy Chevrier, Monique Stefanou, Perla L. Vaca Lopez, Heydon K. Kaddas, Karely M. van Thiel Berghuijs, Echo L. Warner, Giselle K. Perez, Austin R. Waters, Douglas B. Fair, Richard E. Nelson, Mark A. Lewis, Elyse R. Park, Anne C. Kirchhoff

    Published 2025-12-01
    “…We will enroll 300 YA cancer survivors (n = 200 intervention; n = 100 usual care) diagnosed with breast, testicular, lymphoma, sarcoma, colorectal, melanoma, or thyroid cancer between the ages of 26 and 39, who have completed treatment in the past two years. …”
    Get full text
    Article